103 related articles for article (PubMed ID: 22430634)
1. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.
Mizuno H; Nakayama T; Miyata Y; Saito S; Nishiwaki S; Nakao N; Takeshita K; Naoe T
Leukemia; 2012 Oct; 26(10):2269-76. PubMed ID: 22430634
[TBL] [Abstract][Full Text] [Related]
2. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
3. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
4. The role of bortezomib in the treatment of lymphoma.
Barr P; Fisher R; Friedberg J
Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
Hamner JB; Dickson PV; Sims TL; Zhou J; Spence Y; Ng CY; Davidoff AM
Surgery; 2007 Aug; 142(2):185-91. PubMed ID: 17689684
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
12. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
[TBL] [Abstract][Full Text] [Related]
13. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
Sato A; Asano T; Ito K; Asano T
Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
16. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
18. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mantle cell lymphoma: targeting the microenvironment.
Drach J; Seidl S; Kaufmann H
Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
